Table 1. A summary of demographic, CNS collection and treatment data (mean±s.e.m.) for control subjects, subjects with Sz as a whole as well as subjects with MRDS and non-MRDS used in this study.
| n | Age (year) | Sex (M/F) | PMI (h) | pH | RIN | DoI (year) | FRADD | Sui (Y/N) | AChol (Y/N) | Benz (Y/N) | THC (Y/N) | Alc (Y/N) | Other (Y/N) | NicAlert >3 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (A) qPCR | |||||||||||||||
| Controls | 30 | 49±3.0 | 24/6 | 43.6±2.9 | 6.36±0.03 | 8.92±0.14 | |||||||||
| Sz | 30 | 48±3.0 | 24/6 | 40.5±2.4 | 6.30±0.04 | 8.82±0.10 | 22±2.8 | 561±96 | 8/22 | 13/17 | 12/18 | 9/21 | 13/17 | 2/30 | |
| P | 0.91 | 1.00 | 0.41 | 0.14 | 0.56 | ||||||||||
| (B) Microarray | |||||||||||||||
| Controls | 15 | 49±4.4 | 12/3 | 46.1±3.9 | 6.40±0.04 | 8.53±0.15 | 8/15 | ||||||||
| MRDS | 15 | 48±4.1 | 13/2 | 39.4±2.7 | 6.29±0.04 | 8.82±0.10 | 22±4.1 | 642±154 | 4/11 | 7/8 | 7/8 | 4/11 | 6/9 | 0/15 | 8/15 |
| Non-MRDS | 15 | 48±4.1 | 11/4 | 41.5±4.0 | 6.29±0.06 | 8.85±0.10 | 22±4.0 | 480±118 | 4/11 | 6/9 | 5/10 | 5/10 | 7/8 | 2/13 | 8/15 |
| F | 0.009 | 0.69 | 0.9 | 0.59 | 1.34 | ||||||||||
| d.f. | 2,42 | 2,42 | 2,42 | 2,42 | |||||||||||
| P | 0.99 | 0.41 | 0.56 | 0.27 | 0.95 | 0.41 | 1.00 | 0.71 | 0.46 | 0.69 | 0.71 | 0.14 | 1.00 | ||
Abbreviations: AChol, prescribed anticholinergic drugs; Alc, alcohol; Benz, prescribed benzodiazepines; CNS, central nervous system; DoI, duration of illness; F, female; FRADD, final recorded antipsychotic drug dose given as chlorpromazine equivalents/day; M, male; MRDS, muscarinic receptor-deficit schizophrenia; N, no; non-MRDS, subjects with schizophrenia who do not have a deficit in muscarinic receptors; PMI, post-mortem interval; qPCR, quantitative PCR; RIN, RNA Integrity Number; Sui, suicide; Sz, schizophrenia; THC, cannabinoids; Y, yes.
Results from toxicology screens of urine or blood after death identified the presence of cannabinoids, alcohol and other nonprescribed medications that are not freely available from pharmacies or supermarkets.